Selected article for: "antiviral activity and human airway"
Author: Touret, Franck; Driouich, Jean-Sélim; Cochin, Maxime; Petit, Paul Rémi; Gilles, Magali; Barthélémy, Karine; Moureau, Grégory; Mahon, Francois-Xavier; Malvy, Denis; Solas, Caroline; de Lamballerie, Xavier; Nougairède, Antoine
Title: Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2
  • Cord-id: 1m8pe4ze
  • Document date: 2021_7_12
    • ID: 1m8pe4ze
    Snippet: Following the emergence of SARS-CoV-2, the search for an effective and rapidly available treatment was initiated worldwide based on repurposing of available drugs. Previous reports described the antiviral activity of certain tyrosine kinase inhibitors (TKIs) targeting the Abelson kinase 2 against pathogenic coronaviruses. Imatinib, one of them, has more than twenty years of safe utilization for the treatment of hematological malignancies. In this context, Imatinib was rapidly evaluated in clinic
    Document: Following the emergence of SARS-CoV-2, the search for an effective and rapidly available treatment was initiated worldwide based on repurposing of available drugs. Previous reports described the antiviral activity of certain tyrosine kinase inhibitors (TKIs) targeting the Abelson kinase 2 against pathogenic coronaviruses. Imatinib, one of them, has more than twenty years of safe utilization for the treatment of hematological malignancies. In this context, Imatinib was rapidly evaluated in clinical trials against Covid-19. Here, we present the pre-clinical evaluation of imatinib in multiple models. Our results indicated that imatinib and another TKI, the masitinib, exhibit an antiviral activity in VeroE6 cells. However, imatinib was inactive in a reconstructed bronchial human airway epithelium model. In vivo, imatinib therapy failed to impair SARS-CoV-2 replication in a golden Syrian hamster model despite high concentrations in plasma and in the lung. Overall, these results do not support the use of imatinib and similar TKIs as antivirals in the treatment of Covid-19.

    Search related documents:
    Co phrase search for related documents
    • accuracy precision and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • action mode and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action mode and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action research and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • action research and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • activity assessment and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • activity assessment and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4
    • acute respiratory syndrome and adjunctive treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute respiratory syndrome and administrate dose: 1
    • acute respiratory syndrome and local ethic committee: 1
    • acute respiratory syndrome and local ethical committee: 1
    • acute sars cov respiratory syndrome coronavirus and adjunctive treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute sars cov respiratory syndrome coronavirus and administrate dose: 1
    • acute sars cov respiratory syndrome coronavirus and local ethic committee: 1